Medical News

RSS

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

GE Healthcare reaches agreement to acquire Applied Precision

GE Healthcare, a unit of General Electric Company, today announced it has reached an agreement to acquire Applied Precision, Inc., a supplier of innovative cellular imaging technologies for the fast-growing cell biology and biomedical research sectors.

28 Apr 2011

AARP warns against Medicaid block grants

In a five-page policy paper issued Wednesday, the seniors lobby detailed how the proposal to transform the state-federal health care program for the poor into a block grant would, among other things, have an especially negative impact on low-income elderly people and people who depend on long-term care services.

28 Apr 2011

Adolor first quarter net loss decreases to $7.3 million

Adolor Corporation today reported net sales of ENTEREG® (alvimopan) were $7.5 million for the three months ended March 31, 2011, a 42% increase compared to net sales of $5.3 million for the three months ended March 31, 2010.

28 Apr 2011

CBI, Children's Rare Disease Network and Global Genes Project partner for Rare Disease Leadership Summit

The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce a partnership with the Children's Rare Disease Network and The Global Genes Project for the 6th Annual Rare Disease Leadership Summit coming up July 12 - 13, 2011 at the Doubletree Hotel in Washington, D.C.

28 Apr 2011

AquaStar granted U.S. Patent for Portable Capillary Sensor technology used in Capwave ELISA platform

AquaStar Holdings, Inc. is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.

28 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

Merck, Inspire announce expiration of HSR waiting period for cash tender offer

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR") has expired in connection with the previously announced cash tender offer made by Monarch Transaction Corp., a wholly owned subsidiary of Merck, to purchase all of the outstanding shares of common stock of Inspire.

28 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

First Edition: April 28, 2011

Today's headlines feature reports about the varying public responses to plans for the budget and Medicare as well as Senate Majority Leader Harry Reid's intent to bring the House-passed Ryan budget up for a vote.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

ViroPharma reports net sales of $127 million for first quarter 2011

ViroPharma Incorporated reported today its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

28 Apr 2011

Bruker first quarter revenue increases 29% to $357.0 million

Bruker Corporation today reported financial results for the first quarter ended March 31, 2011.

28 Apr 2011

PURE Bioscience introduces new Hard Surface disinfectant

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate antimicrobial, today announced the launch of its proprietary new brand, PURE Hard Surface disinfectant and food contact surface sanitizer at the 2011 California State PTA Annual Convention being held April 28 - May 1 in Long Beach, California.

28 Apr 2011